CanSino Biologics Inc Cash Flow Conversion Efficiency
CanSino Biologics Inc cash flow conversion efficiency. Based on the latest financial reports, CanSino Biologics Inc (CJH) has a cash flow conversion efficiency ratio of -0.066x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-392.00 Million ≈ $-458.29 Million USD) by net assets (€5.97 Billion ≈ $6.98 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CanSino Biologics Inc (2016–2025)
Cash flow conversion efficiency of CanSino Biologics Inc from 2016 to 2025. This chart illustrates how CanSino Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CanSino Biologics Inc (CJH) share price today for real-time trading data and today's change.
CanSino Biologics Inc Cash Flow Conversion Ratio Explained
CanSino Biologics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CanSino Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CanSino Biologics Inc ranked by their cash flow conversion efficiency. Also see CanSino Biologics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Viromed Medical AG
DU:Q11
|
-0.038x |
|
Everbright Jiabao Co Ltd
SHG:600622
|
0.042x |
|
Jereissati Participações S.A.
SA:IGTI3
|
0.010x |
|
Hinova Pharmaceuticals Inc. A
SHG:688302
|
N/A |
|
Hua Eng Wire & Cable Co Ltd
TW:1608
|
0.026x |
|
Ausgold Ltd
AU:AUC
|
-0.012x |
|
Korea New Network Co. Ltd
KQ:058400
|
0.023x |
|
KKR Credit Income Fund
AU:KKC
|
0.040x |
Annual Cash Flow Conversion Efficiency for CanSino Biologics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of CanSino Biologics Inc from 2016 to 2025. Review CanSino Biologics Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €4.95 Billion ≈ $5.79 Billion |
€77.86 Million ≈ $91.02 Million |
0.016x | +145.72% |
| 2024-12-31 | €4.91 Billion ≈ $5.74 Billion |
€-168.79 Million ≈ $-197.33 Million |
-0.034x | +80.16% |
| 2023-12-31 | €5.29 Billion ≈ $6.18 Billion |
€-916.25 Million ≈ $-1.07 Billion |
-0.173x | +32.19% |
| 2022-12-31 | €7.25 Billion ≈ $8.47 Billion |
€-1.85 Billion ≈ $-2.16 Billion |
-0.256x | -206.55% |
| 2021-12-31 | €8.55 Billion ≈ $9.99 Billion |
€2.05 Billion ≈ $2.40 Billion |
0.240x | +516.06% |
| 2020-12-31 | €6.07 Billion ≈ $7.10 Billion |
€-349.93 Million ≈ $-409.11 Million |
-0.058x | +45.05% |
| 2019-12-31 | €1.47 Billion ≈ $1.72 Billion |
€-154.25 Million ≈ $-180.33 Million |
-0.105x | +57.38% |
| 2018-12-31 | €502.32 Million ≈ $587.26 Million |
€-123.64 Million ≈ $-144.55 Million |
-0.246x | -165.51% |
| 2017-12-31 | €607.33 Million ≈ $710.03 Million |
€-56.30 Million ≈ $-65.82 Million |
-0.093x | +42.17% |
| 2016-12-31 | €214.47 Million ≈ $250.74 Million |
€-34.38 Million ≈ $-40.20 Million |
-0.160x | -- |
About CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical … Read more